Reviews

Section edited by Thomas F. Gajewski, MD, PhD and Per Thor Straten, PhD

Fact/data-driven works that cumulate several articles of importance on a particular subject or research area in a review format with the goal of providing the “state of the art” in the field. Includes recent major advances and discoveries, significant gaps in the research, current debates, and/or ideas of where research might go next.

Previous Page Page 2 of 3 Next Page
  1. Review

    Targeting the indoleamine 2,3-dioxygenase pathway in cancer

    Tumor cells escape the immune surveillance system of the host through a process called immune tolerance. Immunotherapy targets molecules that serve as checks and balances in the regulation of immune response. ...

    Yong Wha Moon, Joud Hajjar, Patrick Hwu and Aung Naing

    Journal for ImmunoTherapy of Cancer 2015 3:51

    Published on: 15 December 2015

  2. Meeting report

    Combination immunotherapy: Where do we go from here?

    The remarkable clinical success of cancer immunotherapies targeting the checkpoint receptors CTLA-4 and PD-1 has generated considerable excitement and emboldened efforts to build on this important foundation. ...

    Abigail E. Overacre, Sema Kurtulus, Mario Sznol, Drew M. Pardoll, Ana Anderson and Dario A. A. Vignali

    Journal for ImmunoTherapy of Cancer 2015 3:38

    Published on: 18 August 2015

  3. Review

    Pembrolizumab

    The development of the cytotoxic T-lymphocyte-associated protein 4 inhibitor ipilimumab and its approval in 2011 for the treatment of metastatic melanoma has heralded a new era in immuno-oncology. Subsequently...

    Leila Khoja, Marcus O. Butler, S. Peter Kang, Scot Ebbinghaus and Anthony M. Joshua

    Journal for ImmunoTherapy of Cancer 2015 3:36

    Published on: 18 August 2015

  4. Review

    Immunotherapeutic approaches to ovarian cancer treatment

    Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy administration, current therapeutic options for ovarian cancer patients are inadequate. Immunotherapy offe...

    Cariad Chester, Oliver Dorigo, Jonathan S Berek and Holbrook Kohrt

    Journal for ImmunoTherapy of Cancer 2015 3:7

    Published on: 24 March 2015

  5. Review

    High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014

    Interleukin-2 (IL-2) was historically one of the few treatments for adults with stage IV solid tumors that could produce complete responses (CRs) that were often durable for decades without further therapy. Th...

    Janice P Dutcher, Douglas J Schwartzentruber, Howard L Kaufman, Sanjiv S Agarwala, Ahmad A Tarhini, James N Lowder and Michael B Atkins

    Journal for ImmunoTherapy of Cancer 2014 2:26

    Published on: 16 September 2014

  6. Commentary

    Letter to the editor

    Camilo E Fadul, Jan L Fisher, Thomas H Hampton and Marc S Ernstoff

    Journal for ImmunoTherapy of Cancer 2014 2:22

    Published on: 15 July 2014

  7. Commentary

    Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes

    Cancer registries have proven valuable with respect to validating therapeutic safety and drug efficacy, uncovering real-world implementation practices, and their evolution over time. Modern cancer therapeutics...

    Michael K Wong, Howard L Kaufman, Gregory A Daniels, David F McDermott, Sandra Aung, James N Lowder and Michael A Morse

    Journal for ImmunoTherapy of Cancer 2014 2:20

    Published on: 18 June 2014

  8. Review

    Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer

    Knowledge of the basic mechanisms of the immune system as it relates to cancer has been increasing rapidly. These developments have accelerated the translation of these advancements into medical breakthroughs ...

    Raju R Raval, Andrew B Sharabi, Amanda J Walker, Charles G Drake and Padmanee Sharma

    Journal for ImmunoTherapy of Cancer 2014 2:14

    Published on: 14 May 2014

  9. Review

    Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy

    With the success of ipilimumab and promise of programmed death-1 pathway-targeted agents, the field of tumor immunotherapy is expanding rapidly. Newer targets for clinical development include select members of...

    David A Schaer, Daniel Hirschhorn-Cymerman and Jedd D Wolchok

    Journal for ImmunoTherapy of Cancer 2014 2:7

    Published on: 15 April 2014

  10. Meeting report

    Stem cells and cancer immunotherapy: Arrowhead’s 2nd annual cancer immunotherapy conference

    Investigators from academia and industry gathered on April 4 and 5, 2013, in Washington DC at the Arrowhead’s 2nd Annual Cancer Immunotherapy Conference. Two complementary concepts were discussed: cancer “stem ce...

    Adrian Bot, Maurizio Chiriva-Internati, Andrew Cornforth, Brian J Czerniecki, Soldano Ferrone, Kenneth Geles, Philip D Greenberg, Elaine Hurt, Richard C Koya, Masoud H Manjili, William Matsui, Richard A Morgan, Claudia M Palena, Daniel J Powell Jr, Nicholas P Restifo, David M Spencer…

    Journal for ImmunoTherapy of Cancer 2014 2:6

    Published on: 20 March 2014

  11. Research article

    Statistical issues and challenges in immuno-oncology

    The development of immuno-oncologic agents poses unique challenges, namely that both efficacy and safety profiles differ from previously characterized cytotoxic and pathway-specific agents. In addition, expone...

    Tai-Tsang Chen

    Journal for ImmunoTherapy of Cancer 2013 1:18

    Published on: 21 October 2013

  12. Review

    Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors

    T cells can mediate remarkable tumor regressions including complete cure in patients with metastatic cancer. Genetic alterations in an individual’s cancer cells (the mutanome) encode unique peptides (m-peptide...

    Willem W Overwijk, Ena Wang, Francesco M Marincola, Hans-Georg Rammensee and Nicholas P Restifo

    Journal for ImmunoTherapy of Cancer 2013 1:11

    Published on: 29 July 2013

  13. Review

    Primer on tumor immunology and cancer immunotherapy

    Individualized cancer therapy is a central goal of cancer biologists. Immunotherapy is a rational means to this end—because the immune system can recognize a virtually limitless number of antigens secondary to...

    Timothy J Harris and Charles G Drake

    Journal for ImmunoTherapy of Cancer 2013 1:12

    Published on: 29 July 2013

Previous Page Page 2 of 3 Next Page
JITC logo

Advertisement